[go: up one dir, main page]

PL365779A1 - A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents

A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Info

Publication number
PL365779A1
PL365779A1 PL01365779A PL36577901A PL365779A1 PL 365779 A1 PL365779 A1 PL 365779A1 PL 01365779 A PL01365779 A PL 01365779A PL 36577901 A PL36577901 A PL 36577901A PL 365779 A1 PL365779 A1 PL 365779A1
Authority
PL
Poland
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
PL01365779A
Other languages
English (en)
Polish (pl)
Inventor
Poelje Paul D. Van
Mark D. Erion
Toshihiko Fujiwara
Original Assignee
Metabasis Therapeutics, Inc.
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics, Inc., Sankyo Company, Limited filed Critical Metabasis Therapeutics, Inc.
Publication of PL365779A1 publication Critical patent/PL365779A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL01365779A 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes PL365779A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06

Publications (1)

Publication Number Publication Date
PL365779A1 true PL365779A1 (en) 2005-01-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365779A PL365779A1 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (no)
JP (1) JP2004508297A (no)
KR (1) KR100854851B1 (no)
CN (2) CN101301294A (no)
AU (2) AU7327101A (no)
BR (1) BR0112212A (no)
CA (1) CA2412142A1 (no)
CZ (1) CZ20035A3 (no)
HU (1) HUP0301830A3 (no)
IL (2) IL153513A0 (no)
MX (1) MXPA02012713A (no)
NO (1) NO20030034L (no)
NZ (1) NZ523227A (no)
PL (1) PL365779A1 (no)
RU (1) RU2328308C2 (no)
SK (1) SK62003A3 (no)
WO (1) WO2002003978A2 (no)
ZA (1) ZA200300044B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
HK1042496B (zh) 1998-09-09 2006-01-27 症变治疗公司 新的果糖1，6-二磷酸酶的杂芳族抑制剂
EP1607401A1 (en) 2000-03-08 2005-12-21 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-Bisphosphatase inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
ES2629414T3 (es) 2003-12-26 2017-08-09 Kyowa Hakko Kirin Co., Ltd. Derivados de tiazol
BRPI0514372A (pt) * 2004-08-18 2008-06-10 Metabasis Therapeutics Inc inibidores de tiazol de frutose 1, 6-bisfosfatase
WO2006064744A1 (ja) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited 糖尿病の治療のための医薬組成物
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
EP2394647A1 (en) 2006-11-02 2011-12-14 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114474T1 (de) * 1989-01-24 1994-12-15 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ES2210728T3 (es) * 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
HK1042496B (zh) * 1998-09-09 2006-01-27 症变治疗公司 新的果糖1，6-二磷酸酶的杂芳族抑制剂
CA2354053A1 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
CA2673615C (en) * 2000-01-21 2013-07-16 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
NZ523227A (en) 2005-04-29
JP2004508297A (ja) 2004-03-18
KR20030031952A (ko) 2003-04-23
HUP0301830A3 (en) 2007-10-29
CN1599612A (zh) 2005-03-23
CZ20035A3 (cs) 2003-05-14
WO2002003978A2 (en) 2002-01-17
AU2001273271B2 (en) 2006-01-05
KR100854851B1 (ko) 2008-08-27
IL153513A0 (en) 2003-07-06
EP1372660A2 (en) 2004-01-02
CN100396283C (zh) 2008-06-25
CA2412142A1 (en) 2002-01-17
BR0112212A (pt) 2003-12-30
MXPA02012713A (es) 2004-09-10
SK62003A3 (en) 2003-09-11
WO2002003978A3 (en) 2003-10-16
ZA200300044B (en) 2004-05-06
NO20030034D0 (no) 2003-01-03
RU2328308C2 (ru) 2008-07-10
IL153513A (en) 2014-07-31
CN101301294A (zh) 2008-11-12
AU7327101A (en) 2002-01-21
NO20030034L (no) 2003-03-05
HUP0301830A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
IL153513A0 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
HUP0302950A3 (en) Synergistic herbicidal composition and a process for its use
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB9900416D0 (en) Inhibitors
HUP0301083A3 (en) Synergistical herbicide composition and use thereof
GB0025782D0 (en) Use of inhibitors
PL364904A1 (en) Thiohydantoins and use thereof for treating diabetes
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
PL373301A1 (en) Phosphodiesterase 4 inhibitors
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
GB2361223B (en) Climbing appliance for roping-up and roping-down operations
AU2001261544A1 (en) Metal surface treatment agent
GB0105613D0 (en) Pharmaceutically effective compounds and their use
EP1153022A4 (en) PROTEASE INHIBITORS
EP1222913A4 (en) EPILATOIRES AND AGENTS FOR EXTERNAL USE
GB0202187D0 (en) "Inhibitors"
AU2001264273A1 (en) Amide compounds and use thereof
AU2001269496A1 (en) Surface treating agent for metal member
AUPQ582400A0 (en) A method of treatment and agents for use therein
GB0114572D0 (en) A method for the treatment of textile surfaces and compositions for use therein
HK1062634A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0302212A3 (en) Fungicidal mixture based on amide compounds and its use
HUP0402141A3 (en) Herbicidal composition and process for its use
HUP0500955A3 (en) Cucurbitacin-containing insecticidal composition and a process for its use
AU2002357594A1 (en) Nitrogen-containing heterocyclic compounds and use thereof

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)